GlassScriptPhysician profile
Belena Davis
NPI 1598074361
$3,703.50
in general payments reported to CMS, 2019-2025
35 companies · $1,011 in 2025
The $1,011 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $514 · 2022: $504 · 2023: $777 · 2024: $898 · 2025: $1,011.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,686.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,685.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $861.73 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $467.51 | 2021-2025 | |
| Glaxosmithkline, LLC. | $412.17 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $259.47 | 2023-2025 | Lifevest |
| Astellas Pharma US INC | $253.20 | 2021-2025 | Veozah, Myrbetriq |
| Lilly USA, LLC | $173.32 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Corium, LLC | $132.60 | 2023-2024 | Azstarys, Adlarity |
| Astrazeneca Pharmaceuticals LP | $131.87 | 2024 | Airsupra, Farxiga |
| Daiichi Sankyo INC. | $92.16 | 2022-2025 | Injectafer |
| Lundbeck LLC | $89.56 | 2022-2025 | Vyepti |
| Xeris Pharmaceuticals, INC. | $88.39 | 2023-2025 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $84.33 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.61 | 2021-2025 | Xifaxan |
| Axsome Therapeutics, INC. | $63.75 | 2022-2025 | Auvelity |
| Dexcom, INC. | $57.18 | 2021-2023 | Dexcom G6 Transmitter |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $42.10 | 2023 | |
| Merck Sharp & Dohme LLC | $41.78 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Amarin Pharma, INC. | $41.11 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $31.23 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.56 | 2021 | |
| Pfizer INC. | $28.21 | 2023 | |
| Janssen Pharmaceuticals, INC | $26.96 | 2022 | |
| Ardelyx, INC. | $23.80 | 2025 | Ibsrela |
| Neurocrine Biosciences, INC. | $20.28 | 2025 | |
| Philips North America LLC | $19.67 | 2024 | (Ck7) Extended Holter |
| E.R. Squibb & Sons, L.L.C. | $19.60 | 2024 | Camzyos |
| Sumitomo Pharma America, INC. | $18.30 | 2023 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $17.51 | 2024 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $15.21 | 2021 | |
| Dynavax Technologies Corporation | $15.18 | 2025 | Heplisav-B |
| Cipher Pharmaceuticals US LLC | $14.24 | 2025 | Natroba, Spinosad |
| Abbott Laboratories | $13.66 | 2025 | Eterna |
| Tolmar, INC. | $13.58 | 2024 | |
| Horizon Therapeutics Plc | $13.52 | 2023 | Krystexxa |
| Sanofi-Aventis U.S. LLC | $12.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Belena Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.